Navigation Links
Shire Recognized by ISPE Facility of the Year Awards Program
Date:1/24/2011

LEXINGTON, Mass., Jan. 24, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the Project Atlas manufacturing facility in Lexington, Massachusetts has been recognized with an honorable mention in the ISPE (International Society for Pharmaceutical Engineering) Facility of the Year Awards program.

Project Atlas was selected from a group of 26 state-of-the-art projects constructed in 11 different countries. The Facility of the Year Awards program recognizes pharmaceutical manufacturing projects that utilize new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing high-quality medicines.

Among the reasons given for the recognition, the judges noted Shire's extensive deployment of single-use technologies at commercial scale, and the ability to overcome challenges and make technical adaptations to implement fully single-use upstream process technology at a 2,000 liter scale. As a result, the facility was effectively built faster, with reduced investment and lower utility requirements.

"We are honored to be recognized by ISPE for our work on the Atlas Project," said Bill Ciambrone, Head of Technical Operations at Shire HGT. "In less than three years, we have successfully built, commissioned, and performed validation runs in a facility that enables us to develop therapies to treat those suffering from orphan diseases around the world. As the ISPE judges noted, Project Atlas is the embodiment of Shire's vision – which is to be as brave as the people we help."

The Atlas facility supports the manufacture of REPLAGAL® (agalsidase alfa), VPRIV® (velaglucerase alfa), and Shire's robust pipeline of future development programs.  Along with Atlas, Shire owns four buildings in Lexington that serve as the global center for Shire HGT, the business unit of Shire dedicated to the study of orphan diseases.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Shire plc: PharmaVitae Profile
2. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
3. Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
4. Atrium Recognized by New Hampshire Bio/Medical Council
5. Shire Update on ProAmatine(R) (midodrine HCl)
6. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
7. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
8. Shire Purchases Strategic Site in Massachusetts
9. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
10. Area Residents Can Give a Little, Help A Lot at Shires BIG GIVE
11. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
Breaking Medicine News(10 mins):